BDX vs. MMSI: Which Stock Should Value Investors Buy Now?

An analysis comparing Becton Dickinson (BDX) and Merit Medical (MMSI) for value investors identifies BDX as the superior option. BDX holds a Zacks Rank #2 (Buy) compared to MMSI's #3 (Hold), indicating a stronger earnings outlook, and exhibits more attractive valuation metrics, including a forward P/E of 13.03 versus MMSI's 23.56, a PEG ratio of 1.51 versus 2.42, and a P/B ratio of 2.1 versus 3.4, resulting in a higher Value grade.

Analysis

A comparative valuation analysis between Becton Dickinson (BDX) and Merit Medical (MMSI) identifies BDX as the superior investment for value-focused investors within the Medical - Dental Supplies sector. This conclusion is supported by both earnings outlook and fundamental valuation metrics. BDX holds a Zacks Rank of #2 (Buy), indicating a stronger trend in positive earnings estimate revisions compared to MMSI's #3 (Hold) rank. On a quantitative basis, BDX appears significantly undervalued relative to its peer. It trades at a forward P/E ratio of 13.03, substantially lower than MMSI's 23.56. Furthermore, when accounting for growth expectations, BDX's PEG ratio of 1.51 is considerably more attractive than MMSI's 2.42. The valuation gap is also evident in the price-to-book metric, where BDX has a P/B of 2.1 versus 3.4 for MMSI. These factors culminate in a superior Zacks Value grade of 'B' for BDX, while MMSI receives a 'C', reinforcing the case for BDX as the more compelling value opportunity.

Key Decisions for Investors

• Value-oriented investors should consider Becton Dickinson (BDX) as the more attractive long position due to its superior earnings outlook and significantly more favorable valuation on P/E, PEG, and P/B bases.
• Given Merit Medical's (MMSI) comparatively high valuation and neutral 'Hold' rating, investors may find it prudent to underweight or avoid initiating new positions relative to more attractively priced industry peers.
• The primary driver for BDX's favorable rating is its earnings outlook, so investors should monitor future earnings estimate revisions closely to validate the continuation of this value thesis.